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Variation inCAPN10, the gene encoding the ubiquitously expressed cysteine protease calpain-10, has been associated
with type 2 diabetes in Mexican Americans and in two northern-European populations, from Finland and Germany.
We have studied CAPN10 in white subjects of British/Irish ancestry, using both family-based and case-control
studies. In 743 sib pairs, there was no evidence of linkage at the CAPN10 locus, which thereby excluded it as a
diabetes-susceptibility gene, with an overall sib recurrence risk, lS, of 1.25. We examined four single-nucleotide
polymorphisms (SNP-44, -43, -19, and -63) previously either associated with type 2 diabetes or implicated in
transcriptional regulation of calpain-10 expression. We did not find any association between SNP-43, -19, and
-63, either individually or as part of the previously described risk haplotypes. We did, however, observe significantly
increased ( ) transmission of the less common C allele at SNP-44, to affected offspring in parents-offspringPp .033
trios (odds ratio 1.6). An independent U.K. case-control study and a small discordant-sib study did not show
significant association individually. In a combined analysis of all U.K. studies ( ) and in combination withPp .015
a Mexican American study ( ), the C allele at SNP-44 is associated with type 2 diabetes. Sequencing ofPp .004
the coding region of CAPN10 in a group of U.K. subjects revealed four coding polymorphisms—L34V, T504A,
R555C, and V666I. The T504A polymorphism was in perfect linkage disequilibrium with the diabetes-associated
C allele at SNP-44, suggesting that the synthesis of a mutant protein and/or altered transcriptional regulation could
contribute to diabetes risk. In conclusion, we were not able to replicate the association of the specific calpain-10
alleles identified by Horikawa et al. but suggest that other alleles at this locus may increase type 2 diabetes risk in
the U.K. population.
Introduction
Type 2 diabetes mellitus is a common chronic disorder
affecting 1135 million people worldwide (King et al.
1998). It is characterized by three major metabolic ab-
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normalities: impaired insulin-stimulated glucose uptake in
muscle and fat, alterations in glucose-stimulated insulin
secretion, and increased hepatic glucose production
(American Diabetes Association 1997). Both genetic and
nongenetic factors contribute to its development. Recent
studies have shown that the variation in CAPN10 (MIM
605286), the gene encoding calpain-10, affects suscepti-
bility to type 2 diabetes mellitus in Mexican Americans
and in two northern-European populations: the Swedish-
speaking population of the Botnia region of Finland and
theGerman population of Saxony (Horikawa et al. 2000).
The inheritance of a specific haplotype combination de-
fined by three single-nucleotidepolymorphisms—SNP-43,
-19, and -63—was found to be associated with a three-
fold increased risk. These polymorphisms are in noncod-
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Table 1
Clinical Characteristics of Subjects
No. of Subjects (M:F)
AADa
(years)
BMIa
(kg/m2)
Treatment:
Diet/OHA/Insulinb
(%)
Sib-pair linkage study 1,223 (659:564) 55.6  8.6 28.7  5.4 20/64/16
Case-control study 1:
Trios probands 153 (96:57) 40.1  7.1 32.0  6.8 21/64/15
Controlsc 411(213:198) N/A N/A N/A
Case-control study 2:
Diabetic probands 222 (106:116) 56.0  8.0 28.1  5.4 20/60/20
Adult controls 212 (71:141) 50.4  13.7d 27.0  4.5 N/A
Discordant-sib study:
Diabetic subjects 49 (23:26) 53.5  8.1 30.2  6.3 18/74/8
Unaffected sibs 49 (17:32) 61.0  9.5d 28.0  4.1 N/A
NOTE.— The probands for case-control study 2, as well as the diabetic and nondiabetic sibs in the
discordant-sib study, were taken from the sib-pair families, but, to avoid replication, no individual was
included in more than one association study.
a Data are as mean  SD.
b OHA p oral hypoglycemic agents; N/A p not applicable.
c Birth cohort.
d Age when studied.
Table 2
Sequences of Primers for PCR and Sequencing Exons 1–7 and 9–13 of CAPN10
EXON(S)
PRIMER
(5′r3′)
PRODUCT
SIZE
(bp)Forward Reverse
1 GATTGGGCCGCCTGTCACGTG AACGGCGGACCCTGCGTTCG 501
2 TTCGAAGCCAACATTTAGCTG AGGGCGAACCTCCCTGATGGAGC 647
3 GTGTGCGTTAGAGTTCTCTGCAG AGAATGAGCTGCCAGACCCTC 469
4 GGCTGGCTGGTGACATCAGTG CTTAGTCCTGACAGGGCTGTG 715
5 GTGGGCTGGAGCATCTCCAG AGCAGGGACTCAGGGGCCTTG 378
6 TGCAGAGCTGCTTCGGGTGTGG CAGAGCACGTGCCCAGCACAG 369
7 ACCCTGCCAGGGTTCATGAGG AAGGCAGAAAGACCTGCAGTC 577
9/10 TGGGCCACGGTGCCTTTGTGG CCTCTGAGAGGTTGGAGATGG 1,065
11 GGCTGTATGTGACTCAAGAGG GTGAGGGGCAGGCAGGAGAC 402
12/13 TCTGAGCCTGGAAGGAGAGTC ACCAGCCCCCACAGTGCAAG 528
ing regions of CAPN10 and are believed to alter risk by
affecting the transcriptional regulation of calpain-10
(Horikawa et al. 2000). The presence of SNP-43 and an
adjacent polymorphism, SNP-44, in an enhancer-like el-
ement, as well as the association between the SNP-43
genotype and calpain-10 mRNA levels in skeletal muscle,
is consistent with this hypothesis (Baier et al. 2000; Hor-
ikawa et al. 2000). SNP-43 was also found to be asso-
ciated with measures of insulin action in Pima Indians
with normal glucose tolerance, suggesting that calpain-
10 increases susceptibility to type 2 diabetes through its
effects on the oxidation of glucose in skeletal muscle
(Baier et al. 2000).
The identification of CAPN10 as a candidate gene
for type 2 diabetes susceptibility—and of specific vari-
ants that alter risk—allows us to examine the contri-
bution of this gene to diabetes risk in other populations.
Here, we examine the contribution of CAPN10 to the
development of type 2 diabetes in white subjects of Eng-
lish/Irish ancestry, using family-based and case-control
studies.
Subjects and Methods
Subjects
The clinical characteristics of the British/Irish type
2–diabetic and control subjects used in the linkage and
association studies are summarized in table 1. Linkage
studies were performed on 743 sib pairs from 573 fam-
ilies in the Diabetes UK Warren 2 Repository, which
consists of families of British/Irish origin, each of which
has at least two sibs diagnosed with type 2 diabetes who
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Figure 1 Studies of linkage between CAPN10 region of chromosome 2 and type 2 diabetes in affected sib pairs. The LOD score at various
values of lS is shown. D2S125 is assumed to be ∼3 cM proximal to CAPN10.
Figure 2 Exon-intron organization of CAPN10. The locations of the SNPs described in the text are shown.
are 35–70 years of age (Frayling et al. 2000). Trans-
mission distortion was examined in 153 parents-off-
spring trios from the Diabetes UK Warren 2 Trios Col-
lection (Frayling et al. 1999). Appropriate numbers of
microsatellite markers had been typed in both the sib-
pair and parent-offspring collections to allow confir-
mation of family relationships and to exclude half-sibs.
For case-control association studies, we used 222 di-
abetic probands taken from the sib-pair collection and
two control groups. The first group consisted of a birth
cohort of 411 babies born in Plymouth, England (Mac-
farlane et al. 1999); the second control group consisted
of 212 nondiabetic adults of British/Irish origin who had
normal glucose tolerance as shown by fasting plasma
glucose (!5.5 mmol/liter) and/or an HbA1c within the
normal range (!6%).
A discordant-sib analysis was performed in a sub-
group of 49 families from the Diabetes UK Warren 2
Repository sib-pair collection in whom DNA was avail-
able from nondiabetic sibs. Family members were de-
fined as nondiabetic when (a) a clinical diagnosis of di-
abetes had not been made and (b) they had an HbA1c
within the normal range (!6%). This subgroup was
taken from the same families that contributed the 222
probands. To avoid duplication, we used a nonproband
diabetic sib for the discordant-sib analysis, whereas the
diabetic probands were used in the case-control asso-
ciation study.
Linkage Analysis
Microsatellites of type (CA)n were used for the linkage
analysis. These were genotyped by PCR using fluores-
cently labeled primers, with detection by an ABI 377
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Table 3
Transmission of CAPN10 SNP Alleles from Heterozygous
Parents to Diabetic Offspring
POLYMORPHISM
NO.
x2 (P)Transmitted
Not
Transmitted
SNP-44 54 34 4.55 (.033)
SNP-43 59 48 1.13 (.29)
SNP-19 70 63 .37 (.54)
SNP-63 19 27 1.39 (.24)
NOTE.—Data shown are for allele 2 of each polymorphism.
Table 4
Transmission of CAPN10 SNP-44, -43, -19, and -63 Haplotypes
from Heterozygous Parents to Diabetic Offspring
HAPLOTYPE
FREQUENCY
IN TRIOS
NO.
x2 (P)Transmitted
Not
Transmitted
1111 .16 31 42 1.64 (.20)
1121 .06 50 55 .23 (.63)
1221 .30 47 38 .95 (.33)
2111 .26 45 28 3.95 (.047)
1112 .22 13 24 3.28 (.07)
2112 .004 1 0 … (…)
NOTE.—It was possible to assign unequivocal haplotypes for 427
of the 459 members of the trios. The allele frequencies and transmis-
sion data are for only those subjects in whom unequivocal haplotypes
were assigned.
DNA sequencer (Applied Biosystems). Thirty markers
spanning chromosome 2 that were from Applied Biosys-
tems linkage mapping set 2 were used, the closest to
CAPN10 being D2S125. PCR, electrophoresis, and
analysis of the markers were performed according to the
manufacturer’s protocol.
Genotyping
SNP-43 (CAPN10-g.4852G/A).—Subjects were geno-
typed for this SNP by a mutagenically separated PCR
(MS-PCR) method, which uses a common forward
primer and two allele-specific reverse primers of different
lengths: forward primer, 5′-CATCCATAGCTTCCACG-
CCTC-3′; reverse primer allele 1 (G), 5′-GCTTAGCCT-
CACCTTCAATC-3′; and reverse primer allele 2 (A), 5′-
ATCCTCACCAAGTCAAGCGTTAGCCTCACCTTC-
AAGT-3′. The underlined nucleotides are mismatched to
the template, to improve the allele specificity (Newton
et al. 1989). PCR was performed in a 10-ml volume
containing 1 # PCR buffer (Applied Biosystems), 200
mmol of each dNTP/liter, 1.5 mmol of MgCl2/liter, 0.25
U AmpliTaq Gold (Applied Biosystems), and 40 ng of
genomic DNA. Primer concentrations were 1,000 nmol
of common primer/liter, 1,000 nmol of allele 1 primer/
liter, and 67 nmol of allele 2 primer/liter, giving a 15:1
ratio of short primers to long primer. The cycling con-
ditions were 96C for 12 min; 35 cycles of 94C for 30
s, 57C for 30 s, and 72C for 30 s; and 72Cfor 10
min. The PCR products were separated on a 3%NuSieve
agarose gel (Flowgen) and were visualized by ethidium
bromide staining: allele 1 (G) is 134 bp and, allele 2 (A)
is 152 bp. We validated the MS-PCR method by ge-
notyping 30 samples, using this method and DNA se-
quencing; no inconsistencies were found. In addition, we
typed eight samples in 10 separate reactions, and all
samples were typed correctly on all occasions.
SNP-44 (CAPN10-g.4841T/C).—We also typed this
SNP by an MS-PCR method. The primers used were as
follows: common reverse primer, 5′-CTCATCCTCACC-
AAGTCAAGGC-3′; allele 1 (T) primer, 5′-CAGGGCG-
CTCACGCTTGCTAT-3′; and allele 2 (C) primer, 5′-
GTGGGCAGAGGACTGGTGGGCGCTCACGCTTG-
CTTC-3′. The reaction mixture was the same as that
used for SNP-43; cycling conditions were also the same,
except for the annealing temperature, which was 60C.
The PCR products were separated on 3% NuSieve aga-
rose gel: allele 1 (T) is 60 bp, and allele 2 (C) is 75 bp.
We compared the genotypes of 18 samples, by both this
method and DNA sequencing, and we found no differ-
ences. We also typed six samples 10 times, using MS-
PCR, and all were typed correctly.
SNP-19 (CAPN10-g.7920indel32bp).—This insertion/
deletion polymorphism was amplified by forward and
reverse primers—5′- GTTTGGTTCTCTTCAGCGTG-
GAG-3′ and 5′- CATGAACCCTGGCAGGGTCTAAG-
3′, respectively. PCR was performed in a 10-ml volume
containing 1 # PCR buffer, 200 mmol of each dNTP/
liter, 1.5 mmol of MgCl2/liter, 5% dimethyl sulfoxide,
250 nmol of each primer/liter, 0.25 U of AmpliTaqGold,
and 40 ng of genomic DNA. The cycling conditionswere
94C for 12 min; 35 cycles of 94C for 30 s, 60C for
30 s, and 72C for 30 s; and 72C for 10 min. The PCR
products were separated on a 3% NuSieve agarose gel
(Flowgen): allele 1 (two repeats of 32-bp sequence) is
155 bp, and allele 2 (three repeats) is 187 bp.
SNP-63 (CAPN10-g.16378C/T).—This SNP was typed
by a protocol provided by Dr. Marju Orho-Melander
(Malmo University Hospital, Lund, Sweden). The for-
ward and reverse primers were 5′-AAGGGGGGCCAG-
GGCCTGACGGGGGTGGCG-3′ and 5′-AGCACTCC-
CAGCTCCTGATC-3′, respectively. The PCR conditions
were the same as those for SNP-19, except that the an-
nealing temperature was 62C. PCR products were di-
gested with 2 units of HhaI (NEB) in 1 # NE4 buffer
(NEB) plus 1 # bovine serum albumin, at 37C for 2
h. The digested products were separated on 3%NuSieve
agarose gel. Alleles 1 (C) and 2 (T) are 162 and 192 bp,
respectively.
SNP-110 (CAPN10-g.9803A/G).—This SNP, which
generates the polymorphism T504A, was amplified by
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Table 5
Allele Frequencies of CAPN10 Polymorphisms
POLYMORPHISM
FREQUENCYa
Case-Control Study 1 Case-Control Study 2
Trios
Probands
( )np 153
Population
Controls
( )np 411
Type 2–
Diabetic
Probands
( )np 222
Adult
Controls
( )np 212
SNP-44 .77 .84 .84 .86
SNP-43 .74 .75 .73 .72
SNP-19 .45 .39 .38 ND
SNP-63 .93 .93 .92 ND
a All frequency are for allele 1. ND p not determined.
Table 6
Haplotype Frequencies: SNP-44, -43, -19, and -63 Combinations
HAPLOTYPE
FREQUENCY
Trios
Probands
( )np 153
Population
Controls
( )np 411
Type 2–
Diabetic
Probands
( )np 222
Mexican
Americansa
( )np 98
1111 .16 .16 .14 .12
1112 .06 .07 .08 .23
1121 .30 .36 .35 .32
1221 .26 .25 .27 .27
2111 .22 .16 .15 .06
a Frequencies are those reported by Horikawa et al. (2000).
forward and reverse primers—5′-CGCCATCAGGGCA-
GTGGCCAAGAACAGC-3 and 5′-CAGAGTGATGC-
GGACGCAGCG, respectively. The PCR conditions
were the same as those for SNP-19, and the PCR product
was digested with HhaI, as described for SNP-63. The
digestion products were separated on 3%Metaphor aga-
rose gel (Flowgen). Allele 1 (A [Thr]) is 196 bp, and
allele 2 (G [Ala]) is digested to 172 bp  24 bp.
Resequencing of CAPN10
All the coding-sequence encoding exons (i.e., exons
1–7 and 9–13 [GenBank accession number AF158748])
were sequenced. Each exon was amplified by flanking
primers (table 2) and an Expand long-template PCR kit
(Roche) and were sequenced using a BigDye terminator
kit (Applied Biosystems).
Statistical Analyses
Linkage analyses.—Multipoint nonparametric linkage
analysis was performed by GENEHUNTER (Kruglyak
et al. 1996) and GENEHUNTER-PLUS software (Kong
and Cox 1997). Exclusion analysis was performed by
the “exclude” command of GENEHUNTER, under the
assumption that there was no dominance variance. Allele
frequencies were derived from the family data by the
RECODE program. The position of CAPN10was taken
to be 3 cM distal to D2S125.
Allele-frequency comparisons.—Allele frequencies
were compared, between groups, by a x2 test.
Transmission/disequilibrium test (TDT).—We used the
TDT (Spielman et al. 1993) to test for linkage disequi-
librium between polymorphisms and type 2 diabetes in
the trios. The P values for the number of allele trans-
missions versus the number of nontransmissions were
calculated by x2 tests.
Discordant-sibs analysis.—We performed a discor-
dant-sib analysis by using a second, nonproband affected
sib and a single (the eldest, when there were more than
one) nondiabetic sib from the 49 families in whom there
was at least one unaffected sib. Allele frequencies were
compared by a x2 test.
Results
Linkage Studies
We tested for linkage between the CAPN10 region of
chromosome 2 and type 2 diabetes in a group of affected
sib pairs from the Diabetes UK Warren 2 Repository,
which consists of 573 families with a maximum 743
affected sib pairs. We did not find any evidence for link-
age: the GENEHUNTER-PLUS maximum LOD score
was 0.02, and we were able to exclude an effect, with
a LOD score of 1.25, for the CAPN10 region (fig. 1).
Family-Based Studies: Allele and Haplotype TDT
We typed SNP-44, -43, -19, and -63 (fig. 2) in the 153
trios. There was no significant departure from the ex-
pected Mendelian 50:50 transmission ratio, at either
SNP-43, -19, or -63 (table 3). However, the C allele
(allele 2) at SNP-44 was transmitted more often than
expected to affected offspring ( ).Pp .03
Horikawa et. al. (2000) have shown that haplotypes
formed by SNP-43, -19, and -63 are better able to define
the risk of type 2 diabetes than are individual SNPs. We
constructed haplotypes from these polymorphisms and
SNP-44, using the trios. Unequivocal haplotypes could
be constructed in 427 of the 459 members of the trios.
We found strong linkage disequilibrium between the
four SNPs, with five haplotypes accounting for 99.6%
of haplotypes (table 4). The C allele (allele 2) at SNP-
44 occurred on only one of the common haplotypes
(2111). The transmission of the haplotypes is shown in
table 4. Only the 2111 haplotype, containing the SNP-
44 rare allele, showed greater-than-expected transmis-
sion to diabetic offspring.
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Genotyping of Cases of Type 2 Diabetes and of
Controls
We typed SNP-44, -43, -19, and -63 in 222 type
2–diabetic probands and in 411 population controls,
and we typed SNP-44 and -43 in 212 adult controls.
The allelic frequencies from these analyses are shown in
table 5. The only significant difference was an excess of
allele 2 of SNP-44 in the trios probands, compared with
that in the population controls (.23 vs. .16; ).Pp .005
Haplotypes were constructed under the assumption
that the five principle haplotypes seen in the trios were
the principle haplotypes in both the cases and the con-
trols. The calculated haplotype frequencies are shown
in table 6. There was a clear difference between the U.K.
haplotype frequency and that in Mexican American con-
trols (table 6) previously reported by Horikawa et al.
(2000): U.K. subjects had a lower frequency of the 1112
haplotype (.08 vs. .23; ) and a higher frequencyP ! .0001
of the 2111 haplotype (.15 vs. .06; ).Pp .0003
Assessment of Previously Described Allele and
Haplotype Associations Seen between Calpain 10 and
Type 2 Diabetes
Horikawa et al. (2000) have shown that the 112/121-
haplotype combination of SNP-43, -19, and -63 is as-
sociated with type 2 diabetes both in Mexican Ameri-
cans (odds ratio [OR] 3.02 [95% confidence interval
{95%CI} 1.37–6.64]) and in a Finnish-and-German
group (OR 3.16 [95%CI 1.19–8.40). In our study, there
was no preferential transmission, in the trios, of either
allele 1 at SNP-43 (table 3) or the 112 or 121 haplotypes
(table 4). The common allele at SNP-43 and the high-
risk haplotypes were of similar frequencies in type 2–di-
abetic cases and in controls (table 5 and 6). The 112/
121-haplotype combination was less common than in
Mexican Americans (genotype frequency 4.2% in the
trios probands, 5.0% in the 222 type 2–diabetic pro-
bands, and 6.1% in the population controls) and was
not associated with increased risk in the diabetic pro-
bands in the trios. We estimate that our study had 190%
power, at , to detect an OR of 3.0 for the 112/ap .05
121-haplotype combination of SNP-43, -19, and -63.
Association between SNP-44 and Type 2 Diabetes
Allele 2 at SNP-44 showed transmission distortion in
the trios, with the C allele being transmitted to 54 off-
spring and not being transmitted to 34 offspring (P !
) (table 3). In case-control study 1, the population.03
controls showed an allele frequency similar to that of
the nontransmitted parental alleles; therefore, there was
a significant difference, in the allele frequency of SNP-
44, between the trios probands and the population con-
trols (x2 p 8.01; ) (table 5). The inheritancePp .0047
of the C allele at SNP-44 was associated with increased
risk of type 2 diabetes (OR 1.59 [95%CI 1.15–2.2]).
Haplotype analysis showed that allele 2 was in a hap-
lotype (2111) with the common alleles at SNPs –43, -19,
and -63 in 198% of chromosomes and that this haplo-
type showed both transmission distortion and association
in a manner similar to that seen for allele 2 at SNP-44
(tables 4 and 6). The 111/111-haplotype combination of
SNP-43, -19, and -63 was associated with increased risk,
compared to all other haplotypes (OR 2.04 [95%CI
1.22–3.39]), and this is entirely attributable to the in-
creased risk associated with the SNP-44, -43, -19, and -
63 haplotype, 2111. The highest-risk haplotype combi-
nations when the trios probands were compared to the
controls were 2111/2111 (OR 2.52 [95%CI 1.06–5.97])
and 2111/1111 (OR 2.36 [1.19–4.66]).
Further Studies of SNP44: Case-Control 2 and
Discordant-Sib Analysis
To further examine the potential role of SNP-44, we
used two additional independent studies—another case-
control study and a discordant-sib analysis of 49 fam-
ilies. In a second independent group of cases and controls
(case-control study 2), we compared the frequencies of
SNP-44 (tables 5 and 6). The 222 type 2–diabetic pro-
bands were taken from the type 2–diabetic sib pairs that
were used in the genomewide screen, and the 212 con-
trols were a group of nondiabetic adults (table 1). There
were no significant differences, in allele frequencies at
SNP-44, between these two groups: the frequency of
allele 2 in the cases was .158, versus .144 the controls
( ). Discordant-sib analysis, using only a singlePp .67
affected member and a single unaffected sib for each
family, was possible in 49 families. The C allele occurred
at a frequency of .20 in the cases, versus .17 in the
nondiabetic-sib controls (OR 1.3; ).Pp .53
Sequencing of Coding Region of CAPN10 in U.K.
Subjects with Type 2 Diabetes
CAPN10 consists of 15 exons spanning 31 kb. A com-
plex pattern of alternative splicing generates at least
eight transcripts, with calpain-10a mRNA being the
most abundant in the tissues that have been examined
(Horikawa et al. 2000). We sequenced the calpain-
10a–encoding region (exons 1–7 and 9–13; fig. 2) to
identify coding variants that might be in linkage dise-
quilibrium with SNP-44. We selected 10 subjects for
these studies, including, for each of the five common
haplotypes, a homozygous parent and his or her het-
erozygous child. This enabled us to identify sequence
changes and to assign them to a specific haplotype. We
found four coding polymorphisms: L34V, T504A,
R555C, and V666I. (L34V and R555C were not ob-
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Table 7
CAPN10 Polymorphisms Found, in 10 U.K. Type 2–Diabetic Subjects, by Direct Sequencing
Polymorphism Location
Nucleotide
Changea Amino Acid Change Haplotype(s)
Allele
Frequencyb
( )np 32
SNP-134 5′ UTR 162G/A 2111 .16
SNP-135 5′ UTR 70T/A 2111 .16
SNP-136 Exon 1, codon 34 100C/T L34V (CTGrGTG) 2111 .03
SNP-79 Exon 4, codon 200 5157A/G P200 (CCArCCG) 2111 ND
SNP-110 Exon 10, codon 504 9803A/G T504A (ACCrGCC) 2111 .16
SNP-137 Exon 10, codon 555 9956C/T R555C (CGCrTGC) 1221 .02
SNP-48 Exon 11, codon 620 11098A/G A620 (GCArGCG) 1111, 1112, 1221 ND
SNP-58 Exon 13, codon 661 11751G/A V666I (GTCrATC) 1111 .08
a The reference sequence is the gene sequence (GenBank accession number AF158748); the A of the ATG of
the initiator Met codon is considered to be nucleotide 1.
b ND p not done (silent polymorphism).
Table 8
Replication of Association between CAPN10 SNP-44 C-Allele and Type 2 Diabetes
Case-Control Study 1 Case-Control Study 2 Discordant Sibs Mexican Americans
No. of subjects:
Probands 153 222 49 108
Controls 411 212 49 103
Frequency of C allele:
Probands .232 .158 .20 .102
Controls .163 .144 .17 .058
OR (95%CI) 1.59 (1.15–2.2) 1.1 (.75–1.6) 1.3 (.57–2.9) 1.94 (.90–4.16)
Pa .005 .67 .53 .10
a All values are two tailed. In addition, combined P values were calculated using the method of Spielman and
Ewens (1998; also see Altshuler et al. 2000), which enables pooling of data from familial and case-control association
studies: for the three U.K. studies only, ; for all four studies, . Mantel-Haenszel x2 analysis revealedPp .015 Pp .004
similar results: for the three U.K. studies only, ; for all four studies, .Pp .029 Pp .009
served in Mexican Americans with type 2 diabetes,
whereas T504A and V666I had been found in this pop-
ulation) (fig. 2 and table 7). The frequency of the coding
polymorphisms was estimated by sequencing an addi-
tional 32 subjects (table 7). The only coding polymor-
phism that was present in 18% of the population was
T504A, which appeared to be in linkage disequilibrium
with SNP-44. To assess this further, all members of the
trios were tested for the T504A coding polymorphism.
This confirmed that the Ala504 allele of the polymor-
phism T504A (SNP-110) was in perfect linkage dise-
quilibrium with the C allele (allele 2) at SNP-44. The
rare Val34 allele was found on the same haplotype but
at much lower frequency (3%), which made our sample
size inadequate for more-detailed study of this variant.
Discussion
We have studied the effect that CAPN10 has on the risk
of type 2 diabetes in white subjects of British/Irish an-
cestry in the United Kingdom. We have tested four poly-
morphisms in CAPN10—SNP-44, -43, -19, and -63 (fig.
2)—for linkage and association with type 2 diabetes,
using family-based and case-control methods. We have
selected these polymorphisms because of their prior as-
sociation with either type 2 diabetes (SNP-43, -19, and
-63, either individually or in combination), insulin re-
sistance (SNP-43), or transcriptional regulation of cal-
pain-10 expression (SNP-44 and -43). We did not con-
firm, in our U.K. subjects, the previously described
haplotype associated with type 2 diabetes in Mexican
Americans and in two northern-European populations
(Horikawa et al. 2000). The C allele (allele 2) at SNP-
44 was preferentially transmitted to patients in the trios,
a group of young and obese diabetic subjects (age at
diagnosis [AAD] 40.1  7.1 years; body-mass index
[BMI] 32.0 6.8 kg/m2 [table 1]). The C allele at SNP-
44 was associated with a 1.5–2.5-fold- increased risk of
diabetes in the trios probands, depending on the other
haplotypes inherited with it. The association was ob-
served in both family-based and case-control studies.
However, there was no significant association between
SNP-44 and type 2 diabetes either in a second group of
subjects in a case-control study or in a small discordant-
sib study.
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Although not all individual U.K. studies showed sig-
nificant association when analyzed alone, the trend in
each study was toward the C allele being associated with
type 2 diabetes (table 8). When the studies were com-
bined, the association remained significant ( ) inPp .015
U.K. cohorts (table 8). A similar result is obtained if all
the results in the U.K. diabetic subjects ( ) andnp 424
controls (including the nontransmitted parental alleles)
( ) are combined in a single 2#2 contingencynp 825
table, with association between the C allele at SNP-44
and type 2 diabetes being characterized by anOR of 1.25
(95%CI 1.01–1.56) ( ). The associationbetweenPp .041
SNP-44 and type 2 diabetes in some but not all data sets
is similar to the observation by Altshuler et al. (2000),
in their study of the Pro12Ala PPARg2 polymorphism
and type 2 diabetes. Studies consisting of several hundred
individuals are unlikely to be consistently significant
when (a) the risk allele is uncommon (i.e., frequency
∼.15) in the population and (b) the relative risk is
∼1.2–1.5. The finding that linkage at the CAPN10 locus
is excluded with power sufficient exclude a lS of 1.25 is
consistent with CAPN10 being a minor susceptibility
gene in the United Kingdom. The C allele at SNP-44,
although rare in Mexican Americans (frequency 5.8% in
controls, vs. 10.2% in diabetic subjects), is also associ-
ated with type 2 diabetes in Mexican Americans (Pp
, one tailed) (table 8). When the Mexican SNP-44.05
study is combined with the U.K. studies, the diabetes
remains associated with SNP-44 ( , two tailed).Pp .004
The results in several studies are therefore consistentwith
a role for SNP-44 in the determination of susceptibility
to type 2 diabetes, although additional studies will be
needed to confirm this.
The strongest evidence for SNP-44 contributing to sus-
ceptibility to type 2 diabetes comes from the diabetic
subjects from the parents-offspring trios, rather than
from the group of affected sib pairs; compared with the
probands in the affected sib pairs, the probands in the
trios were younger when diagnosed with type 2 diabetes
and were more obese (AAD 40.1  7.1 years vs. 56.0
 8.0 years; BMI 32.0  6.8 vs. 28.1  5.38 kg/m2
[table 1]). This may reflect that, in the probands in the
trios, genetic factors make a greater contribution to risk
than do nongenetic factors. In subjects with type 2 dia-
betes, the frequency of missense mutations in the insulin-
promoter–factor 1 gene is higher in younger individuals
than in older individuals (Hani et al. 1999; Macfarlane
et al. 1999). Large, population-based studies will be nec-
essary to determine the magnitude of the effect that SNP-
44 and other variations in CAPN10 have on diabetes
risk in U.K. and other European populations.
SNP-44 may either directly alter susceptibility to type
2 diabetes or be in linkage disequilibrium with the dis-
ease-predisposing variant. Functional studies suggest
that SNP-44 plays a role in the transcriptional regula-
tion of CAPN10 (Horikawa et al. 2000). We have also
shown that SNP-44 is in perfect linkage disequilibrium
with the amino acid polymorphism T504A. This poly-
morphism is located in domain T of calpain-10, a region
of unknown function. Thr504 is also not a conserved
amino acid; this residue is Ser in mouse calpain-10. In
addition, the polymorphism L34V, which is located in
domain I, occurs in ∼20% of Ala504 alleles and is a
possible contributing factor (in both human and mouse
calpain-10, this residue is Leu). Functional studies are
necessary to assess the role that T504A and L34V play
in calpain-10 activity.
Variation in CAPN10 has been associated with 2–3-
fold-increased risk of type 2 diabetes, both in Mexican
Americans and, now, in three northern-European pop-
ulations: Finns (Botnia), Germans (Saxony), and British/
Irish (United Kingdom). However, the polymorphisms
and haplotypes associated with diabetes differ between
populations. This may be due to the presence ofmultiple
susceptibility alleles at CAPN10 and/or to different pat-
terns of linkage disequilibrium between these polymor-
phisms and a common causal variant(s). The amino acid
polymorphisms identified in the U.K. subjects were ei-
ther rare (in the case of T540A) or absent (in the case
of R555C) in theMexican American population studied
by Horikawa et al. (2000); these amino acid polymor-
phisms may alter the risks associated with haplotypes
and haplotype combinations originally defined in the
Mexican American population.
The results presented here highlight an important is-
sue that needs to be addressed in replication stud-
ies—that is, replication of specific polymorphisms/al-
leles at a locus, versus replication of the locus. The
results of our studies ofCAPN10 in the U.K. population
do not provide replication of the polymorphisms or hap-
lotypes at CAPN10 that are associated with the highest
risk of type 2 diabetes in theMexican American, Finnish
(Botnia), or German populations (Horikawa et al.
2000); however, they do provide replication at the level
of the locus, CAPN10, with different alleles of this sus-
ceptibility gene being associated with increased risk in
the U.K. population.
In summary, we were not able to replicate the asso-
ciation between the specific calpain-10 alleles identified
by Horikawa et al. (2000) and type 2 diabetes in whites
of British/Irish ancestry. There is evidence that the rare
allele at SNP-44, which is in complete linkage disequi-
librium with the coding polymorphism T504A, plays a
possible role in the susceptibility to type 2 diabetes.
Additional studies, including large, population-based
case-control studies, will provide a better understanding
of the contribution thatCAPN10makes to diabetes risk
in this population.
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